In this paper, after a brief description of the main signaling pathways downstream of IGF1R, we review the latest advances related to the role of the IGF1/IGF1R axis in immune cell regulation and discuss the potential of targeting IGF1R as a strategy to improve the efficacy of current cancer-immunotherapy approaches. The gene discussed is IGF1; the disease is cancer.